DK173151B1 - Fremgangsmåde til oprensning af enkeltkædet og dobbeltkædet vævsplasminogenaktivator - Google Patents

Fremgangsmåde til oprensning af enkeltkædet og dobbeltkædet vævsplasminogenaktivator Download PDF

Info

Publication number: DK173151B1
Authority: DK; Denmark
Prior art keywords: tpa; column; cells; chain; molecular weight
Prior art date: 1986-05-07

Application number

DK198702337A

Other languages

Danish (da)

English (en)

Other versions

DK233787A (da

DK233787D0 (da

Inventor

Mitsuyoshi Morii

Masaharu Ohoka

Toshihiko Suzuki

Katsuyuki Suzuki

Nobuhiro Kawashima

Noriko Morii

Kunizo Mori

Original Assignee

Mitsui Chemicals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-05-07

Filing date

1987-05-07

Publication date

2000-02-14

1986-05-07 Priority claimed from JP10320086A external-priority patent/JPH0779692B2/ja

1987-05-07 Application filed by Mitsui Chemicals Inc filed Critical Mitsui Chemicals Inc

1987-05-07 Publication of DK233787D0 publication Critical patent/DK233787D0/da

1987-11-08 Publication of DK233787A publication Critical patent/DK233787A/da

2000-02-14 Application granted granted Critical

2000-02-14 Publication of DK173151B1 publication Critical patent/DK173151B1/da

Links

108090000373 Tissue Plasminogen Activator Proteins 0.000 title claims description 77
102000003978 Tissue Plasminogen Activator Human genes 0.000 title claims description 77
229960000187 tissue plasminogen activator Drugs 0.000 title claims description 77
238000000034 method Methods 0.000 title claims description 41
230000008569 process Effects 0.000 title claims description 14
210000004027 cell Anatomy 0.000 claims description 27
239000003480 eluent Substances 0.000 claims description 17
239000000203 mixture Substances 0.000 claims description 15
101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 claims description 12
238000010828 elution Methods 0.000 claims description 11
239000004475 Arginine Substances 0.000 claims description 7
150000001409 amidines Chemical class 0.000 claims description 7
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
150000002357 guanidines Chemical class 0.000 claims description 6
230000001605 fetal effect Effects 0.000 claims description 5
201000001441 melanoma Diseases 0.000 claims description 5
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical group NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
229940122618 Trypsin inhibitor Drugs 0.000 claims description 3
210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 3
210000002950 fibroblast Anatomy 0.000 claims description 3
210000003953 foreskin Anatomy 0.000 claims description 3
238000001179 sorption measurement Methods 0.000 claims description 3
239000002753 trypsin inhibitor Substances 0.000 claims description 3
101710162629 Trypsin inhibitor Proteins 0.000 claims description 2
230000002207 retinal effect Effects 0.000 claims description 2
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
210000005253 yeast cell Anatomy 0.000 claims 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 69
239000011780 sodium chloride Substances 0.000 description 35
230000000694 effects Effects 0.000 description 34
230000009467 reduction Effects 0.000 description 23
239000000872 buffer Substances 0.000 description 22
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 20
229920002684 Sepharose Polymers 0.000 description 16
239000012228 culture supernatant Substances 0.000 description 16
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
108090000623 proteins and genes Proteins 0.000 description 14
230000003480 fibrinolytic effect Effects 0.000 description 12
102000001938 Plasminogen Activators Human genes 0.000 description 11
108010001014 Plasminogen Activators Proteins 0.000 description 11
229940127126 plasminogen activator Drugs 0.000 description 11
235000018102 proteins Nutrition 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
230000001419 dependent effect Effects 0.000 description 10
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 10
229920000053 polysorbate 80 Polymers 0.000 description 10
238000007805 zymography Methods 0.000 description 10
239000007788 liquid Substances 0.000 description 9
239000000243 solution Substances 0.000 description 9
108091003079 Bovine Serum Albumin Proteins 0.000 description 8
239000012894 fetal calf serum Substances 0.000 description 8
239000000126 substance Substances 0.000 description 8
108010039627 Aprotinin Proteins 0.000 description 7
208000002109 Argyria Diseases 0.000 description 7
229960004405 aprotinin Drugs 0.000 description 7
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 7
238000002955 isolation Methods 0.000 description 7
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 7
238000004458 analytical method Methods 0.000 description 6
230000008859 change Effects 0.000 description 6
238000000746 purification Methods 0.000 description 6
239000002253 acid Substances 0.000 description 5
235000015165 citric acid Nutrition 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 4
102000009123 Fibrin Human genes 0.000 description 4
108010073385 Fibrin Proteins 0.000 description 4
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
102000013566 Plasminogen Human genes 0.000 description 4
108010051456 Plasminogen Proteins 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
229910052921 ammonium sulfate Inorganic materials 0.000 description 4
235000011130 ammonium sulphate Nutrition 0.000 description 4
229950003499 fibrin Drugs 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000012064 sodium phosphate buffer Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
229920000936 Agarose Polymers 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000012258 culturing Methods 0.000 description 3
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
210000005260 human cell Anatomy 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
108010043984 Erythrina caffra trypsin inhibitor Proteins 0.000 description 2
241000219769 Erythrina latissima Species 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
241000701024 Human betaherpesvirus 5 Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
229960002319 barbital Drugs 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000012847 fine chemical Substances 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
-1 polyethylene glycidylmethacrylate Polymers 0.000 description 2
239000002243 precursor Substances 0.000 description 2
150000003839 salts Chemical group 0.000 description 2
239000011734 sodium Substances 0.000 description 2
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000011282 treatment Methods 0.000 description 2
LEAHFJQFYSDGGP-UHFFFAOYSA-K trisodium;dihydrogen phosphate;hydrogen phosphate Chemical compound [Na+].[Na+].[Na+].OP(O)([O-])=O.OP([O-])([O-])=O LEAHFJQFYSDGGP-UHFFFAOYSA-K 0.000 description 2
238000005406 washing Methods 0.000 description 2
OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
229920003043 Cellulose fiber Polymers 0.000 description 1
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000219766 Erythrina Species 0.000 description 1
108010088842 Fibrinolysin Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102100027612 Kallikrein-11 Human genes 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
BMZSELAUYYGVCY-UHFFFAOYSA-N OB(O)O.CC(O)C(O)=O Chemical compound OB(O)O.CC(O)C(O)=O BMZSELAUYYGVCY-UHFFFAOYSA-N 0.000 description 1
241000233805 Phoenix Species 0.000 description 1
235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
235000011613 Pinus brutia Nutrition 0.000 description 1
241000018646 Pinus brutia Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
150000004753 Schiff bases Chemical class 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
101710152431 Trypsin-like protease Proteins 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
125000003172 aldehyde group Chemical group 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
229910001626 barium chloride Inorganic materials 0.000 description 1
239000011324 bead Substances 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000006193 diazotization reaction Methods 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
229940125532 enzyme inhibitor Drugs 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
235000011167 hydrochloric acid Nutrition 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
235000011147 magnesium chloride Nutrition 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical group OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
229940012957 plasmin Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000008057 potassium phosphate buffer Substances 0.000 description 1
QTYWBJZOZDYCGB-UHFFFAOYSA-L potassium;sodium;2-carboxybenzoate;hydroxide Chemical compound [OH-].[Na+].[K+].OC(=O)C1=CC=CC=C1C([O-])=O QTYWBJZOZDYCGB-UHFFFAOYSA-L 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
239000012264 purified product Substances 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 1
229940039790 sodium oxalate Drugs 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
101150010939 tpa gene Proteins 0.000 description 1
SPOMEWBVWWDQBC-UHFFFAOYSA-K tripotassium;dihydrogen phosphate;hydrogen phosphate Chemical compound [K+].[K+].[K+].OP(O)([O-])=O.OP([O-])([O-])=O SPOMEWBVWWDQBC-UHFFFAOYSA-K 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
YNIRKEZIDLCCMC-UHFFFAOYSA-K trisodium;phosphate;hydrate Chemical compound [OH-].[Na+].[Na+].[Na+].OP([O-])([O-])=O YNIRKEZIDLCCMC-UHFFFAOYSA-K 0.000 description 1
229960001322 trypsin Drugs 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000001810 trypsinlike Effects 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/814—Enzyme separation or purification
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/814—Enzyme separation or purification
- Y10S435/815—Enzyme separation or purification by sorption

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK198702337A 1986-05-07 1987-05-07 Fremgangsmåde til oprensning af enkeltkædet og dobbeltkædet vævsplasminogenaktivator DK173151B1 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP10320086		1986-05-07
JP10320086A JPH0779692B2 (ja)	1986-05-07	1986-05-07	一本鎖ｔ−ＰＡと二本鎖ｔ−ＰＡを分離する方法
JP18685086		1986-08-11
JP18685086		1986-08-11

Publications (3)

Publication Number	Publication Date
DK233787D0 DK233787D0 (da)	1987-05-07
DK233787A DK233787A (da)	1987-11-08
DK173151B1 true DK173151B1 (da)	2000-02-14

Family

ID=26443851

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK198702337A DK173151B1 (da)	1986-05-07	1987-05-07	Fremgangsmåde til oprensning af enkeltkædet og dobbeltkædet vævsplasminogenaktivator

Country Status (8)

Country	Link
US (1)	US4898825A (fr)
EP (1)	EP0245100B1 (fr)
AU (1)	AU590840B2 (fr)
CA (1)	CA1284961C (fr)
DE (1)	DE3780506T2 (fr)
DK (1)	DK173151B1 (fr)
FI (1)	FI96211C (fr)
NO (1)	NO173287C (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6001355A (en) *	1982-12-14	1999-12-14	Dowdle; Eugene Bernard Davey	Pro-tPA for the treatment of thrombosis, embolism and related conditions
JP2507339B2 (ja) *	1986-08-11	1996-06-12	三井東圧化学株式会社	粗ｔＰＡの精製方法
US4898826A (en) *	1987-12-10	1990-02-06	Invitron Corporation	Method to solubilize tissue plasminogen activator
DE3832898A1 (de) *	1988-09-28	1990-04-12	Boehringer Mannheim Gmbh	Praeparat von in prokaryonten exprimiertem plasminogenaktivator
US5676947A (en) *	1989-02-07	1997-10-14	Boehringer Manneheim Gmbh	Method for treating thromboembolic conditions using thrombolytically active proteins
DE3903581A1 (de) *	1989-02-07	1990-08-16	Boehringer Mannheim Gmbh	Gewebs-plasminogenaktivator-derivat
US6326155B1 (en)	1995-03-20	2001-12-04	Dyax Corp.	Engineering affinity ligands for macromolecules
US5612473A (en) *	1996-01-16	1997-03-18	Gull Laboratories	Methods, kits and solutions for preparing sample material for nucleic acid amplification
US5731186A (en) *	1996-02-05	1998-03-24	Schering Aktiengesellschaft	Method for the production of rDSPA α1
IL126044A (en) *	1996-03-20	2006-08-01	Dyax Corp	Engineering affinity ligands for macromolecules
CN107250375A (zh) *	2014-11-06	2017-10-13	科罗拉多州立大学董事会	在血栓溶解剂存在下使用粘弹性分析鉴定新疾病状态
US11187710B2 (en)	2015-06-08	2021-11-30	The Regents Of The University Of Colorado, A Body Corporate	Time independent viscoelastic analysis parameter for prediction of patient outcome
EP3455366A4 (fr)	2016-05-11	2020-02-26	Michael P. Chapman	Analyse de viscoélasticité chez des patients présentant une maladie associée au système cardiovasculaire

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4766075A (en) *	1982-07-14	1988-08-23	Genentech, Inc.	Human tissue plasminogen activator
EP0112122B1 (fr) *	1982-12-14	1991-08-28	South African Inventions Development Corporation	Activateur de plasminogène
PH22337A (en) *	1983-11-21	1988-08-12	Ciba Geigy Ag	Synthesis of fibrinolytic agents by yeast
AU606582B2 (en) *	1985-09-06	1991-02-14	Codon	Methods for the recovery of tissue plasminogen activator

1987
- 1987-04-29 US US07/043,746 patent/US4898825A/en not_active Expired - Lifetime
- 1987-04-30 CA CA000536036A patent/CA1284961C/fr not_active Expired - Lifetime
- 1987-05-01 AU AU72418/87A patent/AU590840B2/en not_active Ceased
- 1987-05-04 FI FI871948A patent/FI96211C/fi not_active IP Right Cessation
- 1987-05-06 NO NO871883A patent/NO173287C/no unknown
- 1987-05-07 DK DK198702337A patent/DK173151B1/da not_active IP Right Cessation
- 1987-05-07 DE DE8787304077T patent/DE3780506T2/de not_active Expired - Fee Related
- 1987-05-07 EP EP87304077A patent/EP0245100B1/fr not_active Expired

Also Published As

Publication number	Publication date
FI871948L (fi)	1987-11-08
FI96211C (fi)	1996-05-27
US4898825A (en)	1990-02-06
NO871883D0 (no)	1987-05-06
EP0245100A3 (en)	1988-01-07
DK233787A (da)	1987-11-08
NO173287B (no)	1993-08-16
EP0245100A2 (fr)	1987-11-11
DK233787D0 (da)	1987-05-07
NO871883L (no)	1987-11-09
DE3780506T2 (de)	1993-01-07
FI96211B (fi)	1996-02-15
CA1284961C (fr)	1991-06-18
AU590840B2 (en)	1989-11-16
DE3780506D1 (de)	1992-08-27
AU7241887A (en)	1987-11-12
NO173287C (no)	1993-11-24
EP0245100B1 (fr)	1992-07-22
FI871948A0 (fi)	1987-05-04

Legal Events

Date	Code	Title	Description
2000-02-14	B1	Patent granted (law 1993)
2003-01-06	PBP	Patent lapsed

Publication	Publication Date	Title
US4752603A (en)	1988-06-21	Plasminogen activator and pharmaceutical composition having thrombolytic activity
US4960702A (en)	1990-10-02	Methods for recovery of tissue plasminogen activator
DK173151B1 (da)	2000-02-14	Fremgangsmåde til oprensning af enkeltkædet og dobbeltkædet vævsplasminogenaktivator
US6670455B1 (en)	2003-12-30	Process for the preparation in pure form of the protease activating blood clotting VII, its proenzyme or a mixture of both proteins by means of affinity chromatography
US4902623A (en)	1990-02-20	Plasminogen activator
JP2001095563A (ja)	2001-04-10	イオン交換クロマトグラフィーによって血液凝固第ｖｉｉ因子を活性化するプロテアーゼ、そのプロ酵素または両タンパク質の混合物を純粋形態で調製する方法
AU606582B2 (en)	1991-02-14	Methods for the recovery of tissue plasminogen activator
EP0218479B1 (fr)	1994-06-22	Procédé pour la production d'un réactif protéique végétal liant du tPA
US6001355A (en)	1999-12-14	Pro-tPA for the treatment of thrombosis, embolism and related conditions
EP0210870B1 (fr)	1991-09-18	Procédé de purification d'un activateur de plasminogène tissulaire brut
EP0276328B1 (fr)	1993-03-10	Procede pour separer l'un de l'autre un tPA Humain Mono-Brin et un tPA Humain Double-Brin
JPH0223158B2 (fr)	1990-05-23
Soeda et al.	1986	Rapid and high-yield purification of porcine heart tissue-type plasminogen activator by heparin-sepharose choromatography
Bansal et al.	2006	Urokinase separation from cell culture broth of a human kidney cell line
CA1333163C (fr)	1994-11-22	Methodes d'isolement de l'activateur tissulaire du plasminogene
US5158882A (en)	1992-10-27	Method for purifying a crude tissue plasminogen activator preparation
EP0275282A1 (fr)	1988-07-27	Procede de purification d'un activateur de plasminogene
JPH0779692B2 (ja)	1995-08-30	一本鎖ｔ−ＰＡと二本鎖ｔ−ＰＡを分離する方法